"By borrowing a tool from bacteria that infect plants, scientists have developed a new approach to eliminate mutated DNA inside mitochondria—the energy factories within cells. Doctors might someday use the approach to treat a variety of mito"...
- Patient Information:
Details with Side Effects
Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Corticosteroids are capable of producing a rise in intraocular pressure.
Loteprednol etabonate is structurally similar to other corticosteroids. However, the number 20 position ketone group is absent. It is highly lipid soluble which enhances its penetration into cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. Based upon in vivo and in vitro preclinical metabolism studies, loteprednol etabonate undergoes extensive metabolism to inactive carboxylic acid metabolites.
Results from a bioavailability study in normal volunteers established that plasma levels of loteprednol etabonate and Δ 1 cortienic acid etabonate (PJ 91), its primary, inactive metabolite, were below the limit of quantitation (1 ng/mL) at all sampling times. The results were obtained following the ocular administration of one drop in each eye of 0.5% loteprednol etabonate 8 times daily for 2 days or 4 times daily for 42 days. This study suggests that limited ( < 1 ng/ml) systemic absorption occurs with LOTEMAX (loteprednol etabonate ophthalmic suspension) .
Post-Operative Inflammation: Placebo-controlled clinical studies demonstrated that LOTEMAX (loteprednol etabonate ophthalmic suspension) is effective for the treatment of anterior chamber inflammation as measured by cell and flare.
Giant Papillary Conjunctivitis: Placebo-controlled clinical studies demonstrated that LOTEMAX (loteprednol etabonate ophthalmic suspension) was effective in reducing the signs and symptoms of giant papillary conjunctivitis after 1 week of treatment and continuing for up to 6 weeks while on treatment.
Seasonal Allergic Conjunctivitis: A placebo-controlled clinical study demonstrated that LOTEMAX (loteprednol etabonate ophthalmic suspension) was effective in reducing the signs and symptoms of allergic conjunctivitis during peak periods of pollen exposure.
Uveitis: Controlled clinical studies of patients with uveitis demonstrated that LOTEMAX (loteprednol etabonate ophthalmic suspension) was less effective than prednisolone acetate 1%. Overall, 72% of patients treated with LOTEMAX (loteprednol etabonate ophthalmic suspension) experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated with 1% prednisolone acetate. The incidence of patients with clinically significant increases in IOP ( ≥ 10 mmHg) was 1% with LOTEMAX (loteprednol etabonate ophthalmic suspension) and 6% with prednisolone acetate 1%.
Last reviewed on RxList: 5/6/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Lotemax Information
Lotemax - User Reviews
Lotemax User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.